Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Receivables - Accured (2022 - 2025)

Crinetics Pharmaceuticals has reported Receivables - Accured over the past 4 years, most recently at $7.8 million for Q4 2025.

  • Quarterly results put Receivables - Accured at $7.8 million for Q4 2025, down 6.02% from a year ago — trailing twelve months through Dec 2025 was $7.8 million (down 6.02% YoY), and the annual figure for FY2025 was $7.8 million, down 6.02%.
  • Receivables - Accured for Q4 2025 was $7.8 million at Crinetics Pharmaceuticals, up from $6.3 million in the prior quarter.
  • Over the last five years, Receivables - Accured for CRNX hit a ceiling of $8.4 million in Q2 2025 and a floor of $1.4 million in Q4 2022.
  • Median Receivables - Accured over the past 4 years was $7.2 million (2025), compared with a mean of $6.1 million.
  • Biggest five-year swings in Receivables - Accured: surged 167.74% in 2024 and later fell 6.02% in 2025.
  • Crinetics Pharmaceuticals' Receivables - Accured stood at $1.4 million in 2022, then skyrocketed by 121.43% to $3.1 million in 2023, then surged by 167.74% to $8.3 million in 2024, then decreased by 6.02% to $7.8 million in 2025.
  • The last three reported values for Receivables - Accured were $7.8 million (Q4 2025), $6.3 million (Q3 2025), and $8.4 million (Q2 2025) per Business Quant data.